ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9724
0.00%
Brent Oil
82.765
0.00%
Bitcoin
62,816.78
-0.12%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Reino Unido
  5. LSE
  6. Hutchmed (china) Limited (HCM)

  7. Hutchmed (china) Limited (HCM) Noticias

HCM Hutchmed (china) Limited

310.00
0.00 (0.00%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Hutchmed (china) Limited HCM London Acción Ordinaria
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 310.00 10:35:23
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
311.00 303.00 314.00 310.00 310.00
más cotizaciones de acciones »
Sector Industrial de la empresa
PHARMACEUTICALS & BIOTECHNOLOGY

Noticias Recientes

Fecha Hora Fuente Noticia
26/4/202410:09ALNCNewsHutchmed notes CHMP's positive opinion for fruiquintinib..
26/4/202407:30UK RNSHutchmed (China) Limited Positive CHMP Opinion for..
22/4/202403:30UK RNSHutchmed (China) Limited Vesting of Awards Under the LTIP
08/4/202403:30UK RNSHutchmed (China) Limited 2023 Annual Report and Notice of..
05/4/202403:30UK RNSHutchmed (China) Limited Data to be Presented at AACR..
02/4/202404:32ALNCNewsHutchmed endometrial cancer treatment application accepted..
02/4/202401:00UK RNSHutchmed (China) Limited HUTCHMED and Innovent Announce NDA..
28/3/202406:08ALNCNewsHutchmed lung cancer treatment accepted for review in China
28/3/202402:00UK RNSHutchmed (China) Limited Savolitinib sNDA Accepted in China
22/3/202405:09ALNCNewsHutchmed begins registration stage for sovleplenib phase 2/3..
22/3/202402:16ALNCNews*CORRECT: Hutchmed China initiates registration for phase 3..
22/3/202402:00UK RNSHutchmed (China) Limited Initiation of Registration Stage of..
14/3/202404:00UK RNSHutchmed (China) Limited LTIP and Share Option Scheme
05/3/202402:30UK RNSHutchmed (China) Limited Vesting of awards under the LTIP
28/2/202411:31ALNCNewsEARNINGS: Hutchmed revenue surges, Craven House's loss..
28/2/202406:45UK RNSHutchmed (China) Limited Publication of Form 20-F
28/2/202405:30UK RNSHutchmed (China) Limited 2023 Full Year Results and Business..
07/2/202403:50ALNCNewsHutchmed hails fruquintinib trial results for gastric cancer..
07/2/202401:00UK RNSHutchmed (China) Limited Presentation of Phase III Data on..
02/2/202403:52ALNCNewsHutchmed says Inmagene exercises option to licence drug..
02/2/202402:37UK RNSHutchmed (China) Limited Inmagene Exercises Option for Two..
01/2/202402:30UK RNSHutchmed (China) Limited HUTCHMED to Announce 2023 Final..
30/1/202403:20ALNCNewsHutchmed celebrates cancer drug approval in hometown of Hong..
30/1/202401:12UK RNSHutchmed (China) Limited HUTCHMED Receives Marketing..
11/1/202404:17ALNCNewsTOP NEWS: Hutchmed Sovleplenib accepted for review by China..
11/1/202401:00RNSNONHutchmed (China) Limited Sovleplenib NDA Granted Priority..
29/12/202302:30UKREGHutchmed (China) Limited Total Voting Rights
29/12/202302:30UKREGHutchmed (China) Limited Blocklisting Six Monthly Return
21/12/202305:36ALNCNewsIN BRIEF: Hutchmed China renews deals with "substantial"..
21/12/202304:00UKREGHutchmed (China) Limited Overseas Regulatory Announcement
13/12/202307:56ALNCNewsHutchmed completes enrolment for fruquintinib trial
13/12/202301:00RNSNONHutchmed (China) Limited Completed Enrollment of Phase..
07/12/202304:04UKREGHutchmed (China) Limited Overseas Regulatory Announcement
01/12/202301:00RNSNONHutchmed (China) Limited Clinical Data to be Presented at..
30/11/202302:30UKREGHutchmed (China) Limited Total Voting Rights
09/11/202306:16ALNCNewsHutchmed hails Takeda's fruquintinib approval from US for..
09/11/202301:00UKREGHutchmed (China) Limited U.S. FDA Approval of FRUZAQLA(TM)..
24/10/202303:30UKREGHutchmed (China) Limited Vesting of awards under the LTIP
16/10/202303:30RNSNONHutchmed (China) Limited Clinical Data to be Presented at..
29/9/202304:12ALNCNewsHutchmed notes Takeda submits fruquintinib drug application..
29/9/202303:30UKREGHutchmed (China) Limited Total Voting Rights
29/9/202303:30RNSNONHutchmed (China) Limited NDA Submission for Fruquintinib in..
14/9/202303:30UKREGHutchmed (China) Limited Director's Share Dealing
12/9/202304:26ALNCNewsIN BRIEF: Hutchmed China finalises patient enrolment for..
12/9/202303:30RNSNONHutchmed (China) Limited Phase IIIb Savolitinib Results at..
12/9/202301:00RNSNONHutchmed (China) Limited Patient Enrollment Completed for..
31/8/202303:30UKREGHutchmed (China) Limited Total Voting Rights
29/8/202303:30ALNCNewsIN BRIEF: China grants Hutchmed's savolitinib breakthrough..
29/8/202301:00RNSNONHutchmed (China) Limited BTD in China for Savolitinib for..
21/8/202302:46ALNCNewsHutchmed China hails trial on sovleplenib meeting primary..

Su Consulta Reciente

LSE
HCM
Hutchmed (china)
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados